Early ctDNA reduction is associated with better overall survival in the Ph 3 trial of tebentafusp in previously untreated metastatic uveal melanoma

被引：0
|
作者：
Sullivan, Ryan
Collins, Laura
Rodrigues, Manuel
Nathan, Paul
Hassel, Jessica C.
Dummer, Reinhard
Kirkwood, John
Rutkowski, Piotr
Baurain, Jean-Francois
Butler, Marcus O.
Schlaak, Max
Ochsenreither, Sebastian
Abdullah, Shaad E.
Holland, Chris
Ranade, Koustubh
Shoushtari, Alexander N.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1035
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients
    Shoushtari, A. N.
    Collins, L.
    Espinosa, E.
    Sethi, H.
    Stanhope, S.
    Abdullah, S.
    Ikeguchi, A.
    Ranade, K.
    Hamid, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S1210 - S1210
  • [2] Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial
    Piperno-Neumann, S.
    Hassel, J. C.
    Rutkowski, P.
    Baurain, J. F.
    Schlaak, M.
    Butler, M. O.
    Sullivan, R. J.
    Dummer, R.
    Kirkwood, J. M.
    Orloff, M.
    Sacco, J. J.
    Ochsenreither, S.
    Joshua, A. M.
    Gastaud, L.
    Curti, B.
    Carvajal, R. D.
    Hamid, O.
    Collins, L.
    Holland, C.
    Nathan, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1289 - S1290
  • [3] Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
    Nathan, Paul
    Hassel, Jessica C.
    Rutkowski, Piotr
    Baurain, Jean-Francois
    Butler, Marcus O.
    Schlaak, Max
    Sullivan, Ryan J.
    Ochsenreither, Sebastian
    Dummer, Reinhard
    Kirkwood, John M.
    Joshua, Anthony M.
    Sacco, Joseph J.
    Shoushtari, Alexander N.
    Orloff, Marlana
    Piulats, Josep M.
    Milhem, Mohammed
    Salama, April K. S.
    Curti, Brendan
    Demidov, Lev
    Gastaud, Lauris
    Mauch, Cornelia
    Yushak, Melinda
    Carvajal, Richard D.
    Hamid, Omid
    Abdullah, Shaad E.
    Holland, Chris
    Goodall, Howard
    Piperno-Neumann, Sophie
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (13): : 1196 - 1206
  • [4] Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
    Hassel, Jessica C.
    Piperno-Neumann, Sophie
    Rutkowski, Piotr
    Baurain, Jean-Francois
    Schlaak, Max
    Butler, Marcus O.
    Sullivan, Ryan J.
    Dummer, Reinhard
    Kirkwood, John M.
    Orloff, Marlana
    Sacco, Joseph J.
    Ochsenreither, Sebastian
    Joshua, Anthony M.
    Gastaud, Lauris
    Curti, Brendan
    Piulats, Josep M.
    Salama, April K. S.
    Shoushtari, Alexander N.
    Demidov, Lev
    Milhem, Mohammed
    Chmielowski, Bartosz
    Kim, Kevin B.
    Carvajal, Richard D.
    Hamid, Omid
    Collins, Laura
    Ranade, Koustubh
    Holland, Chris
    Pfeiffer, Constance
    Nathan, Paul
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (24): : 2256 - 2266
  • [5] UPDATED SURVIVAL OF PATIENTS WITH PREVIOUSLY TREATED METASTATIC UVEAL MELANOMA WHO RECEIVED TEBENTAFUSP
    Sacco, Joseph
    Carvajal, Richard
    Butler, Marcus
    Shoushtari, Alexander
    Hassel, Jessica
    Ikeguchi, Alexandra
    Hernandez-Aya, Leonel
    Nathan, Paul
    Hamid, Omid
    Piulats, Josep
    Rioth, Matthew
    Johnson, Douglas
    Luke, Jason
    Espinosa, Enrique
    Leyvraz, Serge
    Holland, Chris
    McCully, Michelle
    Abdullah, Shaad
    Sato, Takami
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A568 - A568
  • [6] Low baseline macrophage to T cell ratio is predictive of overall survival with tebentafusp in a phase 3 trial in metastatic uveal melanoma.
    Piperno-Neumann, Sophie
    Stanhope, Sarah
    Britton-Rivet, Camille
    Bischetti, Simone
    Abdullah, Shaad
    Collins, Laura
    Ranade, Koustubh
    Leach, Emma
    Rutkowski, Piotr
    CANCER RESEARCH, 2022, 82 (12)
  • [7] Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma
    Salama, A. K. S.
    Cheshuk, V.
    Siveke, J.
    Berrocal, A.
    Abdullah, S. E.
    Lockwood, S.
    McCully, M. L.
    Kee, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S855 - S855
  • [8] Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
    Sacco, Joseph J.
    Carvajal, Richard D.
    Butler, Marcus O.
    Shoushtari, Alexander N.
    Hassel, Jessica C.
    Ikeguchi, Alexandra
    Hernandez-Aya, Leonel
    Nathan, Paul
    Hamid, Omid
    Piulats, Josep M.
    Rioth, Matthew
    Johnson, Douglas B.
    Luke, Jason J.
    Espinosa, Enrique
    Leyvraz, Serge
    Collins, Laura
    Holland, Chris
    Sato, Takami
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (06)
  • [9] Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
    Carvajal, Richard D.
    Butler, Marcus O.
    Shoushtari, Alexander N.
    Hassel, Jessica C.
    Ikeguchi, Alexandra
    Hernandez-Aya, Leonel
    Nathan, Paul
    Hamid, Omid
    Piulats, Josep M.
    Rioth, Matthew
    Johnson, Douglas B.
    Luke, Jason J.
    Espinosa, Enrique
    Leyvraz, Serge
    Collins, Laura
    Goodall, Howard M.
    Ranade, Koustubh
    Holland, Chris
    Abdullah, Shaad E.
    Sacco, Joseph J.
    Sato, Takami
    NATURE MEDICINE, 2022, 28 (11) : 2364 - +
  • [10] Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
    Richard D. Carvajal
    Marcus O. Butler
    Alexander N. Shoushtari
    Jessica C. Hassel
    Alexandra Ikeguchi
    Leonel Hernandez-Aya
    Paul Nathan
    Omid Hamid
    Josep M. Piulats
    Matthew Rioth
    Douglas B. Johnson
    Jason J. Luke
    Enrique Espinosa
    Serge Leyvraz
    Laura Collins
    Howard M. Goodall
    Koustubh Ranade
    Chris Holland
    Shaad E. Abdullah
    Joseph J. Sacco
    Takami Sato
    Nature Medicine, 2022, 28 : 2364 - 2373
12345